Senzime AB - Asset Resilience Ratio

Latest as of December 2025: 20.00%

Senzime AB (SEZI) has an Asset Resilience Ratio of 20.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Senzime AB for a breakdown of total debt and financial obligations.

Liquid Assets

Skr73.97 Million
≈ $7.96 Million USD Cash + Short-term Investments

Total Assets

Skr369.81 Million
≈ $39.80 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Senzime AB's Asset Resilience Ratio has changed over time. See Senzime AB shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Senzime AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SEZI market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr73.97 Million 20.0%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr73.97 Million 20.00%

Asset Resilience Insights

  • Good Liquidity Position: Senzime AB maintains a healthy 20.00% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Senzime AB Industry Peers by Asset Resilience Ratio

Compare Senzime AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Inspiration Healthcare Group PLC
LSE:IHC
Medical Devices 0.15%
Clearpoint Neuro Inc
NASDAQ:CLPT
Medical Devices 0.00%
Guangdong Biolight Meditech Co Ltd
SHE:300246
Medical Devices 0.73%
Semler Scientific Inc
NASDAQ:SMLR
Medical Devices 0.00%
Arcoma AB
ST:ARCOMA
Medical Devices 18.92%
Guangdong Transtek Medical Electronics Co Ltd
SHE:300562
Medical Devices 14.72%
CareRay Digital Medical Technology Co Ltd
SHG:688607
Medical Devices 16.21%
Xylo Technologies Ltd.
NASDAQ:XYLO
Medical Devices 15.76%

Annual Asset Resilience Ratio for Senzime AB (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Senzime AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 20.00% Skr73.97 Million
≈ $7.96 Million
Skr369.81 Million
≈ $39.80 Million
-3.77pp
2024-12-31 23.78% Skr100.94 Million
≈ $10.86 Million
Skr424.53 Million
≈ $45.69 Million
-11.05pp
2023-12-31 34.83% Skr151.01 Million
≈ $16.25 Million
Skr433.54 Million
≈ $46.66 Million
+26.76pp
2022-12-31 8.07% Skr26.04 Million
≈ $2.80 Million
Skr322.68 Million
≈ $34.73 Million
-34.81pp
2021-12-31 42.88% Skr74.87 Million
≈ $8.06 Million
Skr174.62 Million
≈ $18.79 Million
-19.04pp
2020-12-31 61.92% Skr160.31 Million
≈ $17.25 Million
Skr258.89 Million
≈ $27.86 Million
+45.47pp
2019-12-31 16.46% Skr30.90 Million
≈ $3.33 Million
Skr187.76 Million
≈ $20.21 Million
-0.11pp
2018-12-31 16.57% Skr32.67 Million
≈ $3.52 Million
Skr197.16 Million
≈ $21.22 Million
+11.31pp
2017-12-31 5.26% Skr8.74 Million
≈ $940.35K
Skr166.03 Million
≈ $17.87 Million
-1.15pp
2016-12-31 6.41% Skr10.03 Million
≈ $1.08 Million
Skr156.31 Million
≈ $16.82 Million
--
pp = percentage points

About Senzime AB

ST:SEZI Sweden Medical Devices
Market Cap
$80.11 Million
Skr744.41 Million SEK
Market Cap Rank
#20043 Global
#355 in Sweden
Share Price
Skr4.74
Change (1 day)
+1.83%
52-Week Range
Skr4.10 - Skr7.27
All Time High
Skr26.50
About

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive … Read more